Criteria for Evaluation of Novel Markers of Cardiovascular Risk
Mark A. Hlatky, Peter W.F. Wilson(Roslin Institute), Philip Greenland, Barbara V. Howard(Georgetown-Howard Universities Center for Clinical and Translational Science), Mitchell S.V. Elkind, Alan S. Go(Kaiser Permanente), Donna K. Arnett(Columbia University), Christopher M. Kramer(American College of Cardiology), Frank E. Harrell, Priscilla Y. Hsue, Christie M. Ballantyne(Manpower Demonstration Research Corporation), Sidney C. Smith(Brigham and Women's Hospital), Sharon‐Lise T. Normand, Virginia J. Howard, Christopher J. O’Donnell(United States Department of Veterans Affairs), Yuling Hong(Tsan Yuk Hospital), Joseph P. McConnell(Truett-McConnell College), Michael H. Criqui(Hôpital Dupuytren)
Cited by 1,132
Related Papers
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Prediction of Coronary Heart Disease Using Risk Factor Categories
|Circulation|1998|9.6k
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k